Effects of long-term treatment with CJC-1295, a long-acting growth hormone-releasing hormone analog, in GH-deficient mice
Ipamorelin: 100-300 mcg per injection CJC-1295 (no DAC / mod GRF 1-29): 100-300 mcg per injection Frequency: 1-3 injections daily, subcutaneous, ideally on an empty stomach or 90 minutes after the last meal and before sleep Cycle length: 12-24 weeks followed by a 4-to-8-week break to avoid GH receptor downregulation Injection site: Abdomen, approximately 1-2 inches from the navel, rotating sites each injection The pre-sleep injection is prioritized because it coincides with the largest endogenous GH pulse, which occurs roughly 60-90 minutes after sleep onset and is tied to slow-wave sleep [8]
The ghrelin receptor stimulates the secretion (but not synthesis) of stored growth hormone
Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation
Why people use it: Most people interested in ipamorelin want to optimize their GH levels
